stockrowAlumis Inc.
ALMSAlumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million.
- Revenue
- −37.7%
- EPS
- −242.3%
- Free cash flow
- +23.6%
Quarter to June 2026, against a year earlier
Follow ALMS
Alert me
Alumis Inc. (ALMS) Return on invested capital
Alumis Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| MGTX MeiraGTx Holdings PLC compare | 66.6% |
| AKTS Aktis Oncology, Inc. compare | 0.00% |
| OBX Obsidian Therapeutics, Inc compare | 0.00% |
| DNA Ginkgo Bioworks Holdings, Inc. compare | 0.00% |
| LTGO Latigo Biotherapeutics Inc compare | 0.00% |
| ALMS Alumis Inc. | 0.00% |
| GLUE Monte Rosa Therapeutics, Inc. compare | 0.00% |
| IVA Inventiva S.A. Sponsored ADR compare | 0.00% |
| SNDX Syndax Pharmaceuticals, Inc. compare | −83.4% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)